A study was made in 10 patients with brain tumors of the effect of methylprednisolone sodium succinate (Solu-Medrol) on clinical neurological status, intracranial pressure, and periventricular elastance. Significant clinical improvement and reduction in periventricular elastance both occurred within 24 hours of starting treatment, whereas intracranial pressure was not significantly reduced until the 2nd day of therapy.